Clinical, hormonal, radiological and morphological comparison of patients with clinically evident Cushing's disease and patients with silent corticotroph cell adenoma
Abstract
Purpose: The aim of the study was to review our clinical 7 years experiences with silent corticotroph adenoma (SCA) and Cushing disease (CD) with regard to clinical, radiological features, immunohistochemical and surgical outcomes and compare the results between two groups.
Material and Methods: We retrospectively reviewed a series of patients (n=17; SCA 10, CD 7) with corticotroph adenomas and collected biochemical, neuroradiological and pathological data of those during follow-up time.
Results: Mean pre-operative ACTH values of the patients with CD and SCA were 60.4±29.5, 45.5±34.6 pg/mL, respectively. Mean preoperative cortisol of the patient with CD (21.2±4.4 vs 11.5±4.0 mcg/dL) was increased than the patients with SCA measurements’. Patients with SCA had larger pituitary mass (20.4±4.5 vs 8.8±4.0 mm) than the patients with CD. And cavernous sinus invasion also was determined in all patients with SCA. Sparsely granulation staining was more common in all patients with SCA (7/10) or CD (4/7).
Conclusion: SCAs are totally different from functional CD adenomas related with clinical characteristics and postoperative outcomes. SCA can be thought of as a diverse group of pituitary adenomas.
Keywords
pituitary adenomas , silent corticotroph adenomas , clinical comparison
Kaynakça
- 1) Baldeweg SE, Pollock JR, Powell M, Ahlquist J (2005) A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 19(1):38–42
- 2)Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP,: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602, 2003
- 3) Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010;1:80–92.
- 4) Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47:723–729.
- 5) Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med 1978;64(3):492–499
- 6) Guttenberg K, Mayson S, Sawon C, Kharlip J, et al. Prevalence of Clinically Silent Corticotroph Macroadenomas. Clin Endocrinol 2016;85(6):874-880
- 7) Kageyama K, Oki Y, Nigawara T et al. Pathophysiology and treatment of subclinical Cushing’s disease and pituitary silent corticotroph adenomas. Endocr. Journal 2014;61(10):941-8
- 8) Bradley KJ, Wass JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf) 2003;58(1)59-64.
- 9) Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N Yamaguchi-Okada M, Takeuchi Y, Yamada S. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015;26(4):349-355
- 10) DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics of tumors of Endocrine Organs. In: PU K, LH S, editors. World Health Organization Classification of Tumours. IARC Press; City: 2004.
